CoChat

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

Ruof, J, Golay, A, Berne, C, Collin, C, Lentz, J, Maetzel, A · 2005 · International Journal of Obesity

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Objective The aim of this study is to review the clinical and economic rationale for the reimbursement of orlistat in responding obese patients with type 2 diabetes. Methods Data from seven randomized controlled clinical trials of orlistat in overweight and obese patients with type 2 diabetes were pooled. A subgroup analysis involving patients who achieved a response (defined as a weight loss of >/=5% after 12 weeks of treatment) was conducted. The outcomes of the pooled analysis were then used to construct a Markov health economic model covering an 11-y period. The incidences of diabetes-related micro- and macrovascular complications were derived from the United Kingdom Prospective Diabetes Study. The effects of changes in body mass index, and the impact of micro- and macrovascular complications on utilities were derived from published sources. Publicly available cost data were used and are presented here in 2001 Euros. Discounting of 3% was applied. A probabilistic sensitivity analysis was conducted to examine the robustness of results. Results A total of 1249 patients treated with orlistat and 1230 given placebo were eligible for the intent-to-treat analysis. At the end of the study period, 23% of orlistat patients achieved a weight reduction of >/=5%. These patients showed a mean decrease in HbA1C of 1.16%, a weight reduction of 8.6 kg, a reduction in total cholesterol of 5.3% and a reduction in systolic blood pressure of 5.2 mmHg. The base-case economic analysis revealed…

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.ijo.0802925

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Groscurth A, Vetter W, Suter PM . Is the Swiss population gaining body weight? Body mass index insurance applications between 1950 and 1990. Schweiz Rundsch Med Prax 2003; 92: 2191–2200.

Cited by

See all 40

Metadata

Authors
Ruof, J., Golay, A., Berne, C., Collin, C., Lentz, J., & Maetzel, A.
Affiliations
  • F. Hoffmann-La Roche AG (CH)
  • University Hospital of Geneva (CH)
  • Uppsala University Hospital (SE)
  • Roche (Sweden) (SE)
  • University Health Network (CA)
Corresponding author
Ruof, J
Venue
International Journal of Obesity
Published
2005-03-01
Volume
29
Issue
5
Pages
517-523
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W1982184733
Cited by
40
References
30
Citations by year
2024: 2 · 2023: 3 · 2022: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 5 · 2013: 2 · 2012: 1
FWCI
2.55
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • International Journal of Obesity (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
orlistat, type 2 diabetes, obesity, weight loss, cost-effectiveness, drug reimbursement, quality-adjusted life years, HbA1c, microvascular complications, macrovascular complications, Sweden, Switzerland
MeSH terms
Orlistat, Blood Pressure, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Insurance, Health, Reimbursement, Lactones, Obesity, Sweden, Switzerland, Weight Loss, Treatment Outcome, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.